Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Khondrion logo — Bringing energy to life

Khondrion

Bringing energy to life

Founded 2012 The Netherlands The Netherlands 7 employees Grant Biotechnology, Pharmaceutical

General Information

Company Name Khondrion
Founded Year 2012
Location The Netherlands The Netherlands
Employees 7
Industries Biotechnology, Pharmaceutical
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Khondrion. To contact Khondrion, visit khondrion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Khondrion compare?

A PDF of Khondrion and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Khondrion soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Khondrion

We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases

No funding data available for Khondrion yet.

Khondrion Alternatives & Competitors

View All Alternatives
Khondrion vs
RiboNova, Inc.
RiboNova, Inc. United States

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also...

Venture round
7 employees
Biotechnology, Pharmaceutical
Khondrion vs
Cantabio Pharmaceuticals, Inc.
Cantabio Pharmaceuticals, Inc. United States

Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.

Grant
13 employees
Biotechnology, Pharmaceutical
Khondrion vs
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. United States

The era of genetic neuroscience has arrived

IPO
244 employees
Biotechnology, Health Care
View all alternatives

FAQ About Khondrion

Bringing energy to life
Khondrion was founded in 2012.
Khondrion is headquartered in The Netherlands.
Khondrion operates in Biotechnology and Pharmaceutical.
Khondrion has approximately 7 employees.
Top alternatives and competitors to Khondrion include RiboNova, Inc., Cantabio Pharmaceuticals, Inc., Praxis Precision Medicines, Inc., Neuropore Therapies, Inc., Rgenta Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Khondrion and RiboNova, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Khondrion, https://bouncewatch.com/company/khondrion, updated 7 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes